Bruker (BRKR) Now Covered by Analysts at BTIG Research

BTIG Research initiated coverage on shares of Bruker (NASDAQ:BRKR) in a report published on Friday, January 5th, Marketbeat reports. The firm issued a buy rating and a $42.00 target price on the medical research company’s stock.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Bruker from a hold rating to a buy rating and set a $39.00 price objective for the company in a research report on Thursday, January 4th. Evercore ISI assumed coverage on shares of Bruker in a research report on Wednesday, January 3rd. They issued an in-line rating and a $36.00 price objective for the company. Cowen reissued a hold rating and issued a $35.00 price objective on shares of Bruker in a research report on Thursday, December 21st. Morgan Stanley reissued an equal weight rating and issued a $35.00 price objective on shares of Bruker in a research report on Thursday, December 14th. Finally, Citigroup lifted their target price on shares of Bruker from $29.00 to $34.00 and gave the stock a neutral rating in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the stock. Bruker currently has a consensus rating of Hold and a consensus target price of $32.38.

Shares of Bruker (NASDAQ:BRKR) opened at $34.50 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. Bruker has a 52 week low of $21.83 and a 52 week high of $36.53. The stock has a market cap of $5,410.00, a price-to-earnings ratio of 36.70, a price-to-earnings-growth ratio of 2.71 and a beta of 1.12.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The firm had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. During the same period in the previous year, the business earned $0.32 EPS. The company’s revenue was up 10.6% compared to the same quarter last year. equities research analysts anticipate that Bruker will post 1.19 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 22nd. Shareholders of record on Monday, December 4th were issued a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend was Friday, December 1st. Bruker’s dividend payout ratio is currently 17.02%.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Acrospire Investment Management LLC boosted its holdings in Bruker by 496.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 3,185 shares during the period. SG Americas Securities LLC bought a new stake in Bruker in the 2nd quarter valued at about $111,000. Zions Bancorporation bought a new stake in Bruker in the 3rd quarter valued at about $119,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Bruker by 11.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after purchasing an additional 467 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Bruker by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 331 shares during the period. 65.60% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/12/bruker-brkr-earns-buy-rating-from-analysts-at-btig-research.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply